Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beperminogene perplasmid - AnGes

Next Previous
Drug Profile

Beperminogene perplasmid - AnGes

Alternative Names: AMG 0001 01; AMG-0001; Collategene; Hepatocyte growth factor gene therapy - AnGes; HGF Plasmid-AnGes

Latest Information Update: 04 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnGes MG
  • Developer AnGes; Er-Kim Ilac; Kamada
  • Class Antiparkinsonians; Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Gene transference; Hepatocyte growth factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Ischaemic heart disorders; Lymphoedema; Parkinson's disease

Highest Development Phases

  • Preregistration Chronic limb-threatening ischemia
  • Phase II Arteriosclerosis obliterans
  • Phase I/II Lymphoedema
  • No development reported Ischaemic heart disorders; Parkinson's disease

Most Recent Events

  • 30 Jul 2026 9471186: Updated KDM and HE for planned BLA. Other meeting related info updated in KDM. Discontinued development line reverted for the USA region for Chronic Limb-Threatening Ischemia (CLTI) under the PAD qualifier. For the discontinued development line, the qualifier comment was added as “with rest pain.” - Discussed with SME.
  • 17 Jul 2026 US FDA plans BLA for beperminogene perplasmid for Chronic limb-threatening ischemia in patients with peripheral artery disease (PAD) .
  • 20 May 2026 AnGes completes Type B meeting with US FDA for HGF Gene Therapy Product regarding clinical aspects in preparation for the BLA submission

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top